Articles Archives - TT CONSULTANTS

FTO for Fintech and Open Banking Products: What Patent Coverage Around Payment APIs Means for Launch

Vaibhavi Kukreti — Thu, 16 Jul 2026 13:54:55 +0000

Introduction

Fintech founders and product teams frequently underestimate patent risk at launch. The assumption — common in software-first companies — is that the financial services patent landscape is dominated by legacy institutions that rarely enforce against nimble technology companies, and that software-implemented financial methods are difficult to patent following the post-Alice validity challenges. Both assumptions are incomplete in the Open Banking era.

Open Banking has generated a significant and actively evolving patent landscape around payment initiation APIs, account information aggregation methods, consent management systems, and embedded finance infrastructure. That landscape is held by three distinct categories of patent owner with different enforcement behaviours. And the technical architecture mandated by the Open Banking standard — which every UK-regulated AISP, PISP, and CBPII must implement — creates a shared technical infrastructure with patent risk embedded in its implementation layers.

This article covers why fintech FTO is more complex than most software FTO, what the three patent holder categories look like in the Open Banking landscape, and what a complete payment API FTO needs to cover before a UK fintech product launches.

Why Fintech FTO Is More Complex Than Most Software FTO

Fintech FTO has all the methodological complexity of software FTO — method claims that cover processes rather than products, single-entity performance questions, induced infringement risk through platform architectures — plus two additional complications that are specific to the financial services context. As our guide on FTO for software products and method claim mapping covers, method claim FTO requires a different analytical framework from product feature mapping. In fintech, that method claim complexity is amplified by the financial services regulatory architecture and the standards-adjacent patent risk that comes with implementing Open Banking APIs.

Method claims dominate the landscape: The vast majority of commercially significant patents in the Open Banking and payment technology space are drafted as method claims — covering how payment initiation, data aggregation, consent management, or account information retrieval is performed. A fintech product does not ‘have’ these patented methods in the way a hardware product has physical features. It ‘performs’ them when executed. The claim mapping methodology for a fintech FTO must work at the execution step level, not the product feature level.

Three distinct patent holder categories: Unlike most technology sectors where FTO risk is concentrated among a relatively homogeneous set of competitor patent holders, the Open Banking patent landscape has three distinct categories of holders with very different enforcement behaviours. Understanding all three is essential for accurate FTO scope.

Standards-adjacent patent risk: Open Banking mandates a specific technical architecture — the FCA-regulated open banking standards, implemented through the Open Banking Implementation Entity (OBIE) framework and Financial-grade API (FAPI) specifications. Every regulated AISP, PISP, and CBPII implementing these standards is implementing the same technical architecture. Patents that read on the mandated implementation approach represent a risk that is spread across every participant in the Open Banking ecosystem, not just individual product choices.

The Three Patent Holder Categories in the Open Banking Landscape

A complete fintech FTO needs to assess blocking risk across all three patent holder categories. As our analysis of the difference between FTO and infringement analysis covers, FTO is concerned with whether your product performs steps covered by someone else’s claims — not with who those holders are or how likely they are to enforce. But understanding the enforcement behaviour of each holder category is essential for calibrating the commercial risk associated with each blocking patent found.

Category 1: Traditional Financial Institutions Major UK and global banks — Barclays, HSBC, Lloyds, NatWest, and their international equivalents — hold significant patent portfolios covering payment processing methods, account information systems, authentication protocols, and fraud detection algorithms. These patents were filed to protect internal systems before Open Banking mandated open API architectures, but many of their claims read on the implementation patterns that Open Banking-compliant products use. Traditional FIs have historically been selective about fintech enforcement but have become more active as fintech competition has grown.

Category 2: Fintech-Native Companies Established fintech companies — particularly those that built early market positions in payment processing (Stripe, Adyen, Worldpay), account aggregation (Plaid, Yodlee, TrueLayer), and embedded finance (Railsbank/Railsr, Modulr) — hold growing patent portfolios protecting their API architectures, data normalisation methods, and integration frameworks. These companies are more likely than traditional FIs to enforce against direct competitors entering their market space, and their patents are more precisely targeted at the specific technical implementations that Open Banking products use.

Category 3: Non-Practising Entities A third category that fintech teams frequently overlook: NPEs that have accumulated patent portfolios in payment processing technology, data aggregation methods, and financial API protocols. These entities do not build products — they hold patents and enforce them for licensing revenue. NPE activity in fintech has increased as the commercial value of Open Banking implementations has grown. NPE patents are frequently broader and older than the specific Open Banking architecture, but their claims may read on core implementation patterns in ways that create licensing demand.

What to Cover in a Payment API FTO

A complete payment API FTO for a UK fintech product needs to cover four specific technology categories, each with distinct patent claim types and enforcement risk profiles.

Payment initiation method claims. Patents covering the sequence of steps involved in initiating a payment through an open API — the request-response cycle between the PISP, the ASPSP, and the payment scheme. These are the highest-density category in the Open Banking patent landscape and the one where both traditional FI portfolios and fintech-native company portfolios have the most active positions. The claim mapping analysis for payment initiation needs to work at the API call sequence level, covering each step in the payment initiation flow against the method claim elements in each blocking patent.
Data aggregation and account information method claims. Patents covering how account information is requested, retrieved, normalised, and presented to end users or downstream applications. This category is where the fintech-native aggregation companies (Plaid, Yodlee, TrueLayer) have the most concentrated portfolios. For AISPs and data aggregation platforms, this is typically the highest-risk category from a fintech-native company enforcement perspective.
Authentication and consent management patents. Patents covering Strong Customer Authentication (SCA) implementations, OAuth 2.0 consent flow architectures, and the technical protocols governing how end-user consent to data sharing is obtained and managed. These patents frequently involve method claims where the user performs some steps (the consent interaction) and the system performs others — raising the single-entity performance doctrine questions that are central to fintech software FTO analysis.
Embedded finance and BaaS infrastructure patents. A growing category covering the technical architecture of Banking-as-a-Service platforms — how banking capabilities are packaged as APIs and integrated into non-financial products. This is the fastest-growing filing category in the Open Banking adjacent patent space, and the one where NPE accumulation has been most active. For companies building embedded finance products, this category should be included in the FTO scope even if it is not the primary product feature set.

The Open Banking Standard and Its FTO Implications

Standards-adjacent patent risk: Implementing the UK Open Banking standard does not provide immunity from patent risk. Unlike standards-essential patents (SEPs) in wireless communication, where FRAND licensing obligations apply to patents declared essential to the standard, the Open Banking implementation framework does not have an equivalent SEP declaration and FRAND licensing mechanism. A patent that reads on a mandated implementation step in the OBIE framework is not automatically available under FRAND terms just because implementing the step is required for regulatory compliance.

FAPI and the UK OBIE standards: The UK Open Banking Implementation Entity’s API specifications and the Financial-grade API (FAPI) security profile mandate specific technical implementation patterns for payment initiation and account information services. Patents that read on these mandated patterns — such as specific OAuth 2.0 flow implementations, particular request-response structures, or defined data normalisation approaches — represent a risk for every regulated entity implementing the standard, not just individual product design choices.

How to assess whether a patent reads on standard-compliant implementation: For each potentially blocking patent identified in the FTO, the claim mapping analysis should assess not just whether your specific implementation performs the claimed steps, but whether the claim reads on the mandated implementation pattern itself. If a claim reads on the OBIE-mandated implementation, and your product is implementing the standard as required, the FTO assessment needs to flag this as a structural risk that may require a regulatory-context non-infringement argument, a licensing discussion, or a validity challenge against the blocking patent.

“The most underestimated fintech FTO risk is not from the obvious competitor who has built the same product. It is from the patent that reads on the technical architecture mandated by the Open Banking standard — because every participant implementing the standard is performing the same steps. A claim that reads on a mandated implementation is a risk that scales with the entire Open Banking ecosystem, not just with your product.”

How Our FTO Service Covers Fintech and Open Banking Products

Our freedom to operate service covers fintech and Open Banking FTO across all three patent holder categories — traditional financial institution portfolios, fintech-native company patents, and NPE accumulations in payment processing and data aggregation technology — with method claim mapping at the API call sequence level for payment initiation, data aggregation, authentication, and embedded finance infrastructure. For UK-regulated AISPs, PISPs, and embedded finance platforms, we structure FTO analyses to specifically assess whether any blocking patents read on the OBIE-mandated technical architecture rather than treating standards-compliant implementation as automatically cleared. The output gives product teams and their counsel a complete blocking patent picture across all three holder categories, with enforcement behaviour context for each category and a standards-adjacency assessment for any patent that reads on mandated implementation patterns.

Launching an Open Banking or embedded finance product in the UK? The patent landscape combines traditional FI portfolios, fintech-native company patents, and NPE accumulation. Our FTO service covers all three categories with method claim mapping at the API sequence level. → Contact Us

Conclusion: The Takeaway

Open Banking has created a fintech patent landscape that is more complex than most software FTO teams expect. The three-category holder structure — traditional financial institutions, fintech-native companies, and NPEs — requires a broader FTO scope than a standard software product FTO. The method claim dominance requires a different analytical methodology from product feature mapping. And the standards-adjacent risk from patents that read on OBIE-mandated technical architecture is a structural risk that standard-compliant implementation does not automatically resolve.

The fintech FTO that covers all three dimensions — all three holder categories, method claim mapping at the API sequence level, and standards-adjacency assessment — gives product teams a launch picture that reflects the actual patent risk in the Open Banking ecosystem. The one that treats fintech as a low-patent-risk sector misses all three dimensions — and leaves product teams exposed to blocking risk that a properly scoped FTO would have identified before launch.

The post FTO for Fintech and Open Banking Products: What Patent Coverage Around Payment APIs Means for Launch appeared first on TT CONSULTANTS.

FTO in the UPC Era: How to Structure a Search That Accounts for Pan-European Unitary Patent Risk

Vaibhavi Kukreti — Thu, 16 Jul 2026 11:45:04 +0000

Introduction

The Unified Patent Court and Unitary Patent system changed European patent law more fundamentally than any development since the European Patent Convention itself. For FTO strategy, the change is specific and commercially significant: a single European patent that is within the UPC system can now generate a pan-European injunction covering 17 or more member states from a single proceeding. The same patent that, pre-UPC, represented a Germany risk or a France risk now represents a pan-European risk — and the FTO that clears Germany alone no longer clears the European product launch.

As our review of how the Unified Patent Court is shaping Europe’s patent landscape covers, the UPC has established itself as an active and effective pan-European enforcement forum more quickly than many predicted. The case volume, the speed of preliminary injunction proceedings, and the willingness of patentees to use the UPC system for enforcement across multiple markets simultaneously have all developed faster than the more cautious early projections suggested. The FTO that does not account for this enforcement reality is working with an outdated risk framework.

This article covers what the Unitary Patent changes for FTO risk assessment, how to classify blocking patents by their UPC-system status, and how to structure a complete FTO search that accounts for both the pan-European UPC risk and the national enforcement picture for opted-out patents.

What the Unitary Patent Actually Is — and What It Changes for FTO

The pre-UPC bundle patent and its FTO implications: Before the UPC, a European patent granted by the EPO was a ‘bundle’ of national rights. To be enforceable in Germany, it needed to be validated in Germany. To be enforceable in France, it needed to be validated in France. Each national validation was a separate right, enforced by separate national courts, with separate infringement and validity proceedings in each jurisdiction. For FTO, this meant that a blocking European patent represented country-specific risk — a patent validated in Germany was a Germany risk; whether the same patent family was validated in other countries was a separate FTO question.

The Unitary Patent: one right, one court, pan-European enforcement: A Unitary Patent (UP) is a single European patent right that takes effect automatically across all UPC participating states simultaneously, without national validation. It is granted by the EPO through the same examination process as a traditional European patent, but at the post-grant stage the applicant requests unitary effect instead of validating nationally. The UP is then subject to UPC jurisdiction exclusively — enforceable through a single UPC action across all participating states. For FTO, a Unitary Patent in the relevant technology space does not represent a Germany risk or a France risk. It represents a pan-European risk that a single UPC action can enforce across 17+ markets simultaneously.

Traditional EP patents within the UPC system: Traditional European patents that have not been opted out of the UPC also fall within UPC jurisdiction alongside Unitary Patents. Their owners can choose to enforce them through the UPC rather than national courts. For FTO, a non-opted-out traditional EP carries the same pan-European enforcement risk as a Unitary Patent — the patent holder can seek pan-European injunctive relief through a single UPC filing. This means the Unitary Patent is not the only FTO concern in the UPC era — every non-opted-out traditional EP is also a pan-European enforcement risk.

DATA POINT: As of mid-2026, Unitary Patent filings have grown consistently quarter-on-quarter since the UPC launched in June 2023. Major pharmaceutical, electronics, and industrial technology companies are requesting unitary effect at increasing rates. The proportion of new EP grants taking the unitary route is rising across all technology sectors. For FTO teams, this means the proportion of blocking patents carrying pan-European enforcement risk is increasing with each passing quarter.

The Opt-Out Decision and Its FTO Consequences

The opt-out mechanism was introduced to give patent holders time to assess the new system before committing to UPC jurisdiction. As our guide on how to scope a European FTO that covers both UPC and national patent rights covers in detail, opt-out status is now the central input to European FTO scope decisions — because it determines which enforcement framework applies to each blocking patent.

What opt-out means and who uses it: A traditional European patent owner can register an opt-out in the UPC Case Management System, removing their patent from UPC jurisdiction. An opted-out patent reverts to the pre-UPC national enforcement framework — enforceable only through national courts in each validated jurisdiction. Opt-outs are currently most common in pharmaceutical and biotech sectors, where patent holders have been cautious about central revocation risk and preferred the more predictable national enforcement environment. In electronics, software, and industrial technology, opt-out rates are lower — more patent holders have left their traditional EPs within the UPC system.

Two patent populations with different risk profiles: For FTO purposes, the European patent landscape is now divided into two populations. Population 1: Unitary Patents and non-opted-out traditional EPs — pan-European enforcement risk, single UPC action, injunction covering all participating states. Population 2: Opted-out traditional EPs — national enforcement only, pre-UPC country-by-country framework, separate infringement assessment in each validated jurisdiction. An FTO that does not distinguish between these two populations is applying the wrong risk framework to at least one of them.

How to determine opt-out status: Opt-out status is registered in the UPC Case Management System (CMS) and is publicly accessible. For every European patent identified as a potentially blocking candidate in an FTO, opt-out status should be checked in the CMS as a standard step. A patent that is not registered as opted-out is within the UPC system — either as a Unitary Patent or as a non-opted-out traditional EP — and carries pan-European enforcement risk.

Structuring an FTO Search for the UPC Era

A complete UPC-era FTO requires five specific steps that together account for both the pan-European enforcement risk and the national enforcement picture for opted-out patents.

Identify the full patent universe in the technology space. Run a comprehensive search across EPO-granted patents, Unitary Patents in the UPCA register, and national patents at key domestic offices. The search should cover all relevant technology classifications and all patent holders — including non-obvious holders from adjacent industries with European patent positions in the target technology space. This is the foundation of all subsequent classification and risk assessment steps.
Classify each blocking candidate by enforcement regime. For each patent identified as a potentially blocking candidate, check UPC Case Management System records to determine opt-out status. Classify as: (a) Unitary Patent — pan-European UPC enforcement, (b) Non-opted-out traditional EP — pan-European UPC enforcement, (c) Opted-out traditional EP — national enforcement only. This classification determines which risk assessment framework applies to each blocking candidate.
Assess UPC-system patents for pan-European injunction risk. For each Unitary Patent and non-opted-out traditional EP, assess the pan-European infringement risk across all UPC participating states. Consider which UPC local or regional division the patent holder is most likely to file in, the typical preliminary injunction timeline for that division, and what pan-European market exposure the product would face if a preliminary injunction were granted before launch.
Assess opted-out patents under national frameworks. For each opted-out traditional EP, conduct the pre-UPC country-by-country infringement assessment for the jurisdictions where the patent has been validated and where the product has commercial exposure. Opted-out patents revert to national enforcement frameworks — Germany, France, the Netherlands, Italy, and other key markets should each be assessed separately for opted-out patents that have been validated there.
Cover non-UPC jurisdictions separately. The UK, Switzerland, Norway, and Turkey are not UPC participating states. Patents in these countries require separate national FTO assessment regardless of whether they are part of the same patent family as a UPC-system patent. For products with significant commercial exposure in any of these markets, national jurisdiction coverage is a separate workstream from the UPC-system analysis.

“The UPC era FTO has one fundamental new question that the pre-UPC FTO did not have: is this blocking patent in the UPC system or opted out? That question determines whether you are assessing a pan-European risk from a single patent right or a collection of national risks from a bundle of separate rights. Getting the answer right for every blocking candidate is the starting point for structuring an FTO that reflects the actual enforcement landscape.”

The Validity Dimension: Central Attack Risk in the UPC System

What a central revocation action means for blocking patents: The UPC can hear central revocation actions against Unitary Patents and non-opted-out traditional EPs. A successful central revocation action at the UPC Court of First Instance invalidates the patent across all UPC participating states simultaneously. This is the mirror image of the pan-European enforcement risk: the same centralisation that allows a patent holder to enforce pan-European also exposes their patent to pan-European revocation in a single proceeding.

How central attack risk affects FTO strategy: For product teams facing a blocking Unitary Patent or non-opted-out traditional EP that has validity vulnerabilities, central revocation through the UPC is a potential clearance strategy. A successful UPC revocation removes the patent as a blocking right across all participating states simultaneously — more efficiently than the pre-UPC approach of filing separate national invalidity proceedings in each jurisdiction. For FTO strategy, identifying which blocking patents carry central revocation potential is a valuable input to the overall clearance plan.

Bifurcation: infringement and validity in separate proceedings: The UPC allows bifurcation — infringement and validity proceedings can be heard in separate divisions. A local division may hear an infringement action while a central division simultaneously hears a revocation counterclaim. For FTO strategy, this means that a blocking patent with validity vulnerabilities may remain enforceable during the revocation proceedings, and an injunction may be granted before the validity challenge is resolved. FTO teams should account for this bifurcation risk in their launch timeline planning.

How Our FTO Service Covers the UPC Era

Our freedom to operate service covers the full UPC-era patent landscape: Unitary Patent register search, opt-out status verification for all traditional EP blocking candidates, pan-European infringement risk assessment for UPC-system patents, national enforcement assessment for opted-out patents across key European jurisdictions, and coverage of non-UPC jurisdictions including the UK, Switzerland, and Norway. For products launching across multiple European markets, we structure FTO engagements around both the UPC pan-European enforcement risk and the national picture for opted-out patents — giving product teams a complete and accurately risk-weighted European FTO rather than one calibrated for a pre-UPC enforcement environment that no longer exists.

European FTO in the UPC era requires classifying every blocking patent by its enforcement regime — pan-European UPC system or national opted-out. Our service covers opt-out verification, unitary patent risk, and national frameworks for opted-out patents across all key European jurisdictions. → Contact Us

Conclusion: The Takeaway

The Unitary Patent has not created new technology risks or new blocking patents. The patents in your technology space are the same ones that existed before June 2023. What has changed is what those patents can do. A single non-opted-out European patent can now generate a pan-European injunction covering 17+ member states from a single UPC proceeding. The FTO that clears Germany alone does not clear the European launch. The FTO that fails to classify blocking patents by their UPC-system status is applying the wrong risk framework to the most significant change in European patent enforcement in a generation.

Structuring a UPC-era FTO correctly requires one new analytical step that the pre-UPC FTO did not need: classifying every blocking candidate by its enforcement regime before assessing infringement risk. That classification is the foundation of an FTO that accurately reflects European patent blocking risk in 2026 — and the starting point for a launch strategy built on the actual enforcement landscape rather than the one that existed before the UPC changed everything.

The post FTO in the UPC Era: How to Structure a Search That Accounts for Pan-European Unitary Patent Risk appeared first on TT CONSULTANTS.

The Mechanical Engineering Patent Landscape: What a Fragmented Mittelstand IP Picture Means for R&D Teams

Vaibhavi Kukreti — Thu, 16 Jul 2026 11:15:56 +0000

Introduction

The mechanical engineering patent landscape does not behave like the pharma or electronics landscape. In pharma, a handful of global companies hold the vast majority of commercially significant IP. In semiconductors, a similar concentration applies. In mechanical engineering — particularly in Germany, where the sector accounts for a substantial portion of DPMA filing activity — the landscape is defined not by a few dominant holders but by the cumulative depth of thousands of Mittelstand companies, each holding narrow but often highly specific and commercially significant patent positions in their particular product niche.

This fragmentation changes how the landscape should be read. A standard top-holder analysis — identify the 10 largest patent holders, map their technology focus, assess concentration — captures only a fraction of the relevant blocking IP in mechanical engineering. The Mittelstand patent holder with 15 highly specific process patents in a narrow sub-technology area may represent a more significant practical FTO risk for a product entering that niche than a large corporation with 500 broadly filed patents across a dozen technology areas.

This article covers why the mechanical engineering landscape is structurally different, how the DPMA filing data reveals the competitive IP picture, what the Mittelstand portfolio structure looks like in practice, and how to navigate a fragmented landscape for R&D strategy decisions.

Why the Mechanical Engineering Landscape Is Structurally Different

Not dominated by a few large holders: In most technology-intensive industries, a Herfindahl-Hirschman analysis of patent ownership would reveal a high concentration ratio — a small number of companies holding a disproportionate share of commercially relevant IP. In German mechanical engineering, the concentration ratio is materially lower. The sector’s IP is distributed across a large number of medium-sized companies, each with deep specialisation in a specific mechanical, process, or systems engineering niche. The landscape is wide rather than tall — broad in the number of holders, deep in the specificity of each holder’s IP position within their niche.

The Mittelstand as the defining patent filing structure: Germany’s Mittelstand — the large body of medium-sized, often family-owned, highly specialised industrial companies that form the backbone of German manufacturing exports — is also the defining structure of the mechanical engineering patent landscape. These companies typically have between 200 and 2,000 employees, a single primary product category, and a patent portfolio that reflects decades of incremental innovation within that category. The portfolio depth within the niche is often greater than that of a large corporation filing broadly across many technology areas.

How fragmentation affects FTO and R&D strategy: For product companies entering German mechanical engineering market segments, the fragmented Mittelstand landscape creates specific FTO challenges. Blocking IP may be held by companies that are not obvious competitors — because they are niche specialists rather than broad-based competitors — and may not appear in a standard competitor-focused patent search. A German mechanical engineering FTO that searches only large, well-known companies produces a systematically incomplete scope.

How the DPMA Filing Picture Defines the Landscape

The DPMA’s annual filing data provides the clearest picture of where German mechanical engineering patent activity is concentrated and how it is evolving. Our analysis of the most prominent applicants at the DPMA in 2024 shows that filing volume remains concentrated in transport and mechanical engineering — the DPMA’s two largest technology field categories — with electrification and digitalisation as the fastest-growing sub-categories within both. For mechanical engineering specifically, the DPMA data reveals three distinct clusters of activity.

Cluster 1: Transport and Drivetrain Mechanical Engineering The largest single cluster in German mechanical engineering patent activity. Automotive drivetrain components, transmission systems, chassis engineering, braking systems, and powertrain integration patents dominate the volume. The largest filers in this cluster are Bosch, Continental, Schaeffler, and ZF Friedrichshafen — but beneath these large Tier 1 suppliers sits a dense layer of Mittelstand component specialists with deep process and design patents in specific drivetrain sub-systems.

Cluster 2: Industrial Machinery and Process Equipment The second-largest cluster covers industrial machinery, process equipment, packaging systems, printing technology, and production automation. This is the most Mittelstand-dominated cluster — the large filers (Siemens, Heidelberger Druckmaschinen, Krones) account for a smaller share of the total filing activity than in the transport cluster. The majority of commercially significant IP is held by specialists in specific machine types or process equipment categories.

Cluster 3: Measurement Instruments and Precision Mechanics A distinct cluster covering metrology, coordinate measurement, precision cutting, and mechanical sensing systems. Carl Zeiss, Mahr, and Hexagon hold significant positions, but the landscape is also shaped by a large number of precision engineering Mittelstand companies with deep IP in specific measurement applications. This cluster has the highest density of narrow, highly specific process patents per filing volume.

What the Mittelstand IP Picture Looks Like in Practice

Deep but narrow — the characteristic Mittelstand portfolio structure: A typical Mittelstand mechanical engineering patent portfolio has between 20 and 150 active patents, concentrated almost entirely within the company’s core product category. A packaging machinery specialist may hold 40 patents covering specific sealing mechanisms, film handling systems, and integration interfaces for their machine type. None of those patents is commercially significant outside the packaging machinery niche. All of them are potentially highly significant for a company developing or entering that niche.

Process patents as the primary Mittelstand IP mechanism: Mittelstand mechanical engineering companies tend to file more process patents than product patents — reflecting the fact that their competitive advantage often lies in how they manufacture or assemble something rather than in a novel product design. Process patents are more difficult to identify in a standard product-feature FTO search, because they describe manufacturing methods rather than product configurations. A German mechanical engineering FTO that does not explicitly cover process patents in the relevant manufacturing category risks missing the most commercially significant Mittelstand IP category.

Defensive filing culture: The Mittelstand tends to file patents defensively — to protect existing market positions rather than to build IP for licensing revenue. This means the portfolio structure is often highly aligned with the actual product the company sells, with little dead wood in the form of broadly filed speculative claims. For R&D teams, this defensive filing culture means the Mittelstand landscape is an accurate map of what these companies actually use and protect — making it a reliable input to whitespace analysis in ways that a landscape dominated by broadly filed speculative patents might not be.

“The Mittelstand patent portfolio tells you exactly where that company has built its market position, because it is filing to protect what it actually makes. A cluster of 30 narrow process patents around a specific machine configuration is not a broad IP claim on a technology area — it is a very specific fence around a very specific product. Understanding that fence is the starting point for R&D positioning around it.”

How to Navigate a Fragmented Landscape for R&D Strategy

The standard top-holder analysis is an insufficient starting point for mechanical engineering R&D strategy decisions. Our guide on how patent landscape analysis can enhance your R&D strategy covers how landscape outputs translate into concrete R&D investment and filing decisions — and for mechanical engineering specifically, three methodological adaptations are required to produce an accurate landscape from which R&D strategy can be developed.

Sub-classification search rather than top-holder search. In a fragmented landscape, the most relevant blocking IP is not held by the largest companies — it is held by niche specialists whose portfolios are concentrated in the specific sub-technology area the R&D programme is targeting. A landscape analysis should be scoped to the relevant DPMA and EPO sub-classifications for the target technology, not built from the patent portfolios of the 10 largest mechanical engineering companies. This approach surfaces the Mittelstand specialists whose IP is directly relevant to the R&D programme.
Explicit process patent coverage. Any mechanical engineering landscape analysis should include explicit search coverage for process patents in the relevant manufacturing and assembly categories. These patents do not appear in a product-feature search and require a separate process-oriented search methodology using manufacturing and process-specific classification codes alongside the product technology codes.
Whitespace identification at the sub-classification level. In a fragmented landscape, whitespace tends to exist at sub-classification boundaries — in the spaces between the niche positions held by different Mittelstand specialists, or in the integration layer between established mechanical sub-systems where no single specialist has built a comprehensive IP position. Whitespace identification in mechanical engineering requires sub-classification-level granularity, not a high-level technology area mapping.

How Our Landscape Analysis Service Covers Mechanical Engineering

Our patent landscape analysis service covers the German mechanical engineering patent landscape with sub-classification-level search methodology, explicit process patent coverage, and Mittelstand-aware niche specialist identification alongside the large Tier 1 supplier landscape. For R&D teams assessing market entry into specific German mechanical engineering sub-categories, we provide a landscape analysis that reflects the actual competitive IP structure — including the niche Mittelstand positions that standard top-holder analysis consistently misses — with whitespace identification at the sub-classification level where R&D investment can build defensible IP positions.

Entering a German mechanical engineering market segment? The landscape is defined by fragmented Mittelstand IP, not a few dominant holders. Our analysis covers sub-classification-level niche positions and process patents — the two categories standard searches miss. → Contact Us

Conclusion: The Takeaway

The mechanical engineering patent landscape is not a concentration story — it is a fragmentation story. The IP that matters most for R&D strategy and market entry decisions is held not by a handful of large companies but by hundreds of Mittelstand specialists with deep, narrow portfolios precisely aligned with their product niches. Standard top-holder analysis captures the large Tier 1 suppliers but misses the niche layer where the most commercially significant blocking IP for any specific product category is likely to sit.

Navigating this landscape accurately requires sub-classification-level search methodology, explicit process patent coverage, and whitespace identification at the niche boundary level. The fragmented landscape is not an easier landscape to navigate — it is a different landscape, requiring a different analytical approach from the concentrated landscape that characterises pharma, electronics, or software patent analysis. Getting that approach right is the starting point for R&D investment decisions that reflect the actual mechanical engineering IP picture.

The post The Mechanical Engineering Patent Landscape: What a Fragmented Mittelstand IP Picture Means for R&D Teams appeared first on TT CONSULTANTS.

The Life Sciences Patent Landscape: What Novo Nordisk and Leo Pharma Filing Patterns Tell R&D Teams

Vaibhavi Kukreti — Thu, 16 Jul 2026 09:39:08 +0000

Introduction

Denmark’s life sciences patent landscape is defined, to a degree unusual even among smaller nations, by two companies. Novo Nordisk and Leo Pharma together account for the majority of commercially significant Danish pharmaceutical patent activity — but in fundamentally different ways that create different competitive IP dynamics for R&D teams approaching their therapeutic spaces.

Novo Nordisk operates at global scale in diabetes, obesity, and rare bleeding disorders, with a patent portfolio that stretches from foundational GLP-1 molecule patents to device and digital health filings. Leo Pharma operates with therapeutic depth in dermatology and rare skin diseases, with a patent position that reflects decades of focused R&D in a smaller but less contested IP space. As our analysis of the importance of patent landscape analysis to business strategy covers, understanding who holds the IP and how their filing strategy is structured is the starting point for any credible R&D investment or market entry decision. In Nordic life sciences, that understanding begins with these two companies.

This article maps the filing patterns of both companies, identifies what those patterns tell R&D teams about where the competitive IP is concentrating, and locates the whitespace that exists within and around each portfolio.

Why These Two Companies Define the Nordic Life Sciences Patent Landscape

Novo Nordisk: scale and therapeutic breadth: Novo Nordisk is consistently ranked among the top 10 global pharmaceutical patent filers. Its portfolio spans the full development arc of GLP-1-based therapeutics — from the foundational semaglutide compound patents through formulation, delivery device, and combination product patents — alongside significant positions in insulin, haemophilia treatments, and growth hormone therapeutics. The filing concentration in GLP-1 and obesity is now the largest single therapeutic area in the portfolio by active patent count, reflecting both the commercial success of Ozempic and Wegovy and the R&D investment surge in next-generation GLP-1 applications.

Leo Pharma: depth and specialisation: Leo Pharma’s portfolio is smaller in absolute volume but deeper in specific therapeutic areas. Dermatology — atopic dermatitis, psoriasis, and inflammatory skin diseases — is the core of the portfolio, with active compound, formulation, and biological patents covering both topical and systemic treatment approaches. Rare skin diseases represent a growing and less crowded filing category within the portfolio, reflecting Leo Pharma’s strategic investment in orphan disease indications where the IP landscape is less dense and the regulatory incentives are stronger.

How their different strategies create different landscape dynamics: A company entering Novo Nordisk’s primary therapeutic spaces — particularly GLP-1-based obesity and diabetes treatment — faces a landscape that is exceptionally dense, actively evolving, and defended by a company with the legal and financial resources to enforce it aggressively. A company entering Leo Pharma’s therapeutic spaces faces a landscape that is deep in specific sub-categories but more accessible in adjacent areas where Leo Pharma’s filing has not concentrated. These are structurally different competitive IP environments requiring different landscape analysis approaches.

Novo Nordisk’s Portfolio: What the Filing Patterns Reveal

Novo Nordisk’s filing strategy in GLP-1 and obesity is one of the most instructive examples of how a pharmaceutical company builds and defends a therapeutic franchise through layered IP. Our analysis of the GLP-1 innovations and techno-commercial landscape covers the broader competitive dynamics — and from a patent landscape perspective, the Novo Nordisk filing picture has four distinct layers that together define the competitive IP picture in this space.

Layer 1: Foundational GLP-1 Compound Patents The core semaglutide, liraglutide, and related GLP-1 analogue compound patents. These foundational patents define the basic molecular territory. Many of the earliest compound patents are approaching expiry, but SPCs and continuation strategies have extended effective protection in key markets. For any company developing a GLP-1-based therapeutic, the foundational compound landscape is the first layer to map.

Layer 2: Formulation and Delivery Patents A dense secondary layer covering oral formulations, depot injections, microneedle delivery, combination formulation approaches, and device-drug combination systems. This is the fastest-growing layer of the portfolio and the one creating the most practical FTO challenges for competitors developing alternative delivery mechanisms for GLP-1 or adjacent mechanisms.

Layer 3: Digital Health and Device Integration Patents A growing body of patents covering smart pen injection devices, continuous monitoring integration, app-connected dosing systems, and AI-assisted treatment management. This layer reflects Novo Nordisk’s investment in connected diabetes management and creates cross-domain FTO risk at the device-software boundary.

Layer 4: Next-Generation Mechanism Patents GLP-1/GIP dual agonists, GLP-1/glucagon dual agonists, oral GLP-1 next-generation formulations, and combination therapies. This is where the most recent filing activity is concentrated and where the competitive landscape is most actively being built. The whitespace in this layer is narrowing rapidly.

Where whitespace exists around the Novo Nordisk landscape: Despite the density of the Novo Nordisk portfolio, genuine whitespace exists in specific sub-categories. Next-generation delivery mechanisms — transdermal, inhalation, and subcutaneous depot formulations using novel excipient systems — are areas where Novo Nordisk’s filing concentration is lower relative to the commercial opportunity. Combination approaches involving non-GLP-1 mechanisms are a second area where the landscape is less dense. For R&D teams with differentiated technology in these spaces, early filing creates a structural advantage before Novo Nordisk’s continuation strategy closes the available claim territory.

Leo Pharma’s Portfolio: What the Filing Patterns Reveal

Dermatology: the core filing concentration: Leo Pharma’s dermatology portfolio covers atopic dermatitis (topical corticosteroids, calcineurin inhibitors, and JAK inhibitor-based biologics), psoriasis (both topical and systemic treatments, including biologic formulation patents), and inflammatory skin disease management systems. The portfolio is deep in compound, formulation, and treatment method patents for these core indications. For companies developing competing or complementary therapies in atopic dermatitis or psoriasis, a Leo Pharma-specific landscape analysis is a necessary input to both FTO scoping and R&D positioning.

Rare skin diseases: a growing and less crowded category: Leo Pharma has invested in orphan designation indications including epidermolysis bullosa, ichthyosis, and Darier’s disease. The patent landscape in these rare dermatological conditions is less dense than in mainstream atopic dermatitis and psoriasis — reflecting both the smaller number of competitors and the earlier stage of treatment development. For R&D teams with rare skin disease programmes, the Leo Pharma landscape defines the existing IP boundaries, and the whitespace beyond those boundaries is more accessible than in the core therapeutic areas.

What Leo Pharma’s filing depth means for adjacent R&D: Leo Pharma’s depth in dermatology formulation — particularly topical delivery systems and penetration-enhancing formulation technologies — creates filing positions that extend beyond dermatology into adjacent drug delivery applications. For companies developing topical or transdermal delivery systems for non-dermatological indications, Leo Pharma’s formulation patents represent a cross-domain FTO consideration that a dermatology-only landscape analysis might not flag.

Reading the Broader Nordic Life Sciences Landscape

Beyond the two dominant holders: The Nordic life sciences patent landscape extends beyond Novo Nordisk and Leo Pharma. Zealand Pharma holds growing positions in peptide therapeutics — particularly GLP-1/glucagon dual agonists and amylin analogues — that compete with and complement Novo Nordisk’s next-generation mechanism filing activity. Genmab holds significant positions in antibody technology and bispecific antibody approaches relevant to oncology and inflammatory disease. Coloplast, primarily a medtech company, holds relevant positions in wound care and ostomy technology that intersect with dermatology at the wound healing boundary.

Generic and biosimilar entry considerations: The Nordic life sciences patent landscape has a specific relevance for generic and biosimilar manufacturers planning Scandinavian market entry. Denmark has an active pharma patent enforcement environment with particular experience in SPC disputes and biosimilar market entry cases. The Danish Maritime and Commercial Court has handled a significant number of pharmaceutical patent disputes and has developed relevant expertise in both originator infringement claims and biosimilar entry challenges. For generic manufacturers, the landscape analysis needs to cover not just patent density but the SPC extension layer that may significantly extend effective protection beyond the base patent expiry dates.

How Our Landscape Analysis Service Covers Nordic Life Sciences

Our patent landscape analysis service covers the Nordic life sciences patent landscape at the company-specific level — Novo Nordisk, Leo Pharma, Zealand Pharma, and the broader competitive field — with filing trend analysis by therapeutic area, SPC extension mapping, and whitespace identification in the sub-categories where competitive IP concentration is lower relative to the commercial opportunity. For R&D teams assessing entry into Novo Nordisk’s or Leo Pharma’s primary therapeutic spaces, we provide a landscape analysis that reflects the full layered portfolio structure of each company — compound, formulation, device, and next-generation mechanism patents — not just a high-level patent count by therapeutic area.

Mapping the Nordic life sciences patent landscape for R&D investment or market entry decisions? Our service covers the filing patterns of Novo Nordisk, Leo Pharma, and the broader competitive field — with whitespace identification at the sub-therapeutic level. → Contact Us

Conclusion: The Takeaway

The Nordic life sciences patent landscape is not one story. It is two distinct competitive IP structures sitting side by side — Novo Nordisk’s global-scale, multi-layered GLP-1 and diabetes portfolio, and Leo Pharma’s therapeutic-depth dermatology and rare skin disease portfolio. Each creates a different competitive IP environment for R&D teams approaching those therapeutic spaces. And each has a distinct whitespace picture that a company-specific filing pattern analysis reveals more accurately than a general pharmaceutical patent count.

For R&D teams making investment and market entry decisions in Nordic life sciences, the landscape analysis that matters is the one that maps how each dominant holder has structured their IP position, where the filing concentration is highest, and where the genuine claim space remains. That analysis starts with Novo Nordisk and Leo Pharma — and extends from there to the competitive field that operates in and around their therapeutic territories.

The post The Life Sciences Patent Landscape: What Novo Nordisk and Leo Pharma Filing Patterns Tell R&D Teams appeared first on TT CONSULTANTS.

FTO for Pharmaceutical Products: How SPC Extensions and Domestic Patents Affect Your Clearance

Vaibhavi Kukreti — Wed, 15 Jul 2026 13:24:20 +0000

Introduction

Swiss pharmaceutical market entry is one of the most patent-intensive product launch decisions a pharma company can make. Switzerland is home to Novartis and Roche — two of the world’s largest patent-holding pharmaceutical companies — alongside dozens of specialty pharma, biotech, and medtech companies with significant domestic and international patent portfolios. The blocking IP picture for a Swiss pharma product launch has three dimensions that most international FTO analyses handle incompletely: the EPO patent layer, the domestic IPI patent layer, and the SPC extension layer.

Getting all three dimensions right is not just a thoroughness question. It is a commercial question. An SPC that extends protection on a key compound patent by five years represents five additional years of market exclusivity for the originator. A generic or biosimilar manufacturer that misses an active SPC in its FTO — or that treats SPC validity as equivalent to underlying patent validity without a separate assessment — may launch into blocked territory without understanding the full extent of the clearance problem.

This article covers the two-layer structure of Swiss pharma FTO, how SPC extensions work in Switzerland, why SPC validity requires a separate assessment from underlying patent validity, and how to build a complete Swiss pharmaceutical FTO that accounts for all three dimensions.

The Two Layers of Swiss Pharma FTO That Both Require Coverage

The Swiss patent landscape has two structurally distinct layers that together define the full IP picture for a pharmaceutical product. As our analysis of what Switzerland’s Patent Act revision means for IP landscape strategy covers, most competitive IP analysis focuses on the EPO layer and systematically underweights the domestic Swiss patent layer. For pharma FTO, this gap is commercially material.

Layer 1: EPO-Granted Patents Validated in Switzerland European patents granted by the EPO can be validated in Switzerland through the standard EPO national phase process. These patents are governed by Swiss law for infringement and validity purposes, litigated before the Swiss Federal Patent Court, and assessed at EPO-comparable claim scope. This is the layer most international FTO analyses cover. It is necessary but not sufficient.

Layer 2: Domestic IPI-Granted Swiss Patents Switzerland has its own domestic patent system administered by the Swiss Federal Institute of Intellectual Property (IPI). Swiss domestic patents are separate rights from EPO-validated European patents — not equivalent, not interchangeable. Major Swiss pharma companies including Novartis and Roche hold significant domestic Swiss patent portfolios covering compound variants, formulation methods, manufacturing processes, and combination therapy approaches. An FTO that covers only EPO-validated patents misses this layer entirely.

Why the domestic layer is frequently underweighted: International FTO teams unfamiliar with Switzerland often treat EPO patent coverage as comprehensive for the Swiss market. It is not. The domestic IPI layer represents a distinct body of patent rights that requires separate searching of the IPI database alongside EPO patent searches. For pharma compounds and formulations where Swiss domestic filing supplements European patent strategy, missing the IPI layer means missing blocking patents that may have a different — and potentially longer — effective protection scope than the EPO-validated counterparts.

How SPC Extensions Work in Switzerland

What an SPC is: A Supplementary Protection Certificate (SPC) is a separate intellectual property right that extends the effective protection of a pharmaceutical or medtech patent beyond its standard 20-year term. SPCs exist to compensate patent holders for the time lost to regulatory approval processes — the period between the patent filing date and the date of first marketing authorisation for the product. In Switzerland, SPCs are governed by the Swiss Patent Act and can extend protection by up to five years.

Swiss SPC requirements: To obtain a Swiss SPC, a patent holder must hold an underlying patent that is still in force, have received a first marketing authorisation in Switzerland for the product covered by the patent, and file the SPC application within six months of either the patent grant or the marketing authorisation date, whichever is later. The SPC attaches to the underlying patent and expires at most five years after the patent’s normal expiry date. The product protected by the SPC must be the subject of a valid marketing authorisation.

How SPC expiry dates change the effective blocking timeline: For pharma FTO, the SPC expiry date — not the underlying patent expiry date — is the date that determines when the compound, formulation, or product covered by the SPC becomes available for generic or biosimilar market entry. A compound patent that appears to expire in 2026 may carry an SPC that extends effective protection to 2031. An FTO analysis that relies on patent expiry dates without checking SPC status will consistently underestimate the effective blocking period for products where SPCs are in force.

SPC CONTEXT: Switzerland has a distinct SPC system from the EU SPC Regulation. Swiss SPCs are granted by the IPI under Swiss national law. The validity requirements and the relationship between the SPC and the underlying marketing authorisation are governed by Swiss law, not EU law. For products that have EU marketing authorisation but separate Swiss marketing authorisation, the SPC analysis needs to be conducted under Swiss SPC rules rather than assuming equivalence with EU SPC outcomes.

SPC Validity as a Separate FTO Assessment

SPC validity is one of the most frequently overlooked dimensions of Swiss pharma FTO. Our analysis of the Swiss Federal Patent Court’s expedited nullity proceedings and their implications for pharma portfolios highlights that SPC validity is a separate question from underlying patent validity — both need to be assessed before proceedings commence, because a successful challenge to an SPC can open market entry even where the underlying patent remains valid.

Why SPC validity is not the same as underlying patent validity: A Swiss SPC can be invalid even if the underlying patent is valid and in force. SPC invalidity arises when the SPC was granted on the basis of a marketing authorisation that does not cover the product protected by the patent, when the underlying patent does not actually protect the product as required by the SPC rules, or when the SPC application was filed out of time. These are SPC-specific validity grounds that are entirely separate from the novelty, inventive step, and enablement grounds on which the underlying patent itself can be challenged.

Common SPC validity vulnerabilities: The most frequent SPC validity issues in Swiss pharma are: (1) the scope of the marketing authorisation does not align with the scope of the patent claims as required for SPC grant; (2) the patent does not protect the active ingredient as required by Swiss SPC rules; and (3) where the product received marketing authorisation in the EU before Switzerland, the Swiss SPC term calculation may contain errors. For each blocking SPC identified in the FTO, a validity pre-screen covering these SPC-specific grounds is a necessary step before treating the SPC as a solid blocking right.

How to assess SPC validity risk in an FTO context: A preliminary SPC validity assessment reviews the IPI’s SPC grant file, checks the scope alignment between the marketing authorisation product and the patent claims, verifies the SPC term calculation, and identifies whether any of the common SPC invalidity grounds apply. SPCs identified as potentially invalid on SPC-specific grounds are flagged as challenge candidates in the FTO output — giving the product team the information they need to decide whether to challenge the SPC or design around the protected product.

“The SPC that appears to block your Swiss market entry may be invalid on grounds entirely separate from the underlying patent. A blocking SPC with a scope alignment problem — where the marketing authorisation product does not match the patent claims as required by Swiss SPC rules — is challengeable in FPC nullity proceedings. The FTO that identifies this gives the product team an option the FTO that treats the SPC as unquestionable does not.”

Building a Complete Swiss Pharma FTO

Cover both patent layers. Run separate searches on the EPO database (for patents validated in Switzerland) and the IPI database (for domestic Swiss patents). Do not assume that EPO patent coverage is comprehensive for the Swiss market. Identify all active patents in both databases that are relevant to the target product’s compound, formulation, manufacturing process, and therapeutic use.
Identify all active SPCs for the target product category. Search the IPI’s SPC register for all active SPCs that could cover the target product or its active ingredient. Cross-reference the SPC register against the patent layer search to identify which blocking patents have active SPC extensions, and determine the SPC expiry date for each. The SPC expiry date — not the patent expiry date — is the effective market entry date for products covered by an active SPC.
Assess SPC expiry dates and effective blocking periods. For each active blocking SPC, calculate the effective blocking period from today’s date to the SPC expiry date. Where the SPC expiry date is more than 12 months away, include the SPC in the blocking risk assessment at its full effective scope. Where the SPC expiry date is within 12 months, flag it as an approaching expiry that may open market entry within the commercial planning horizon.
Assess SPC validity risk for each blocking SPC. For each active blocking SPC that represents a material commercial obstacle, conduct a preliminary SPC validity assessment covering scope alignment, patent-product correspondence, and SPC term calculation accuracy. SPCs with identified validity vulnerabilities are flagged as challenge candidates alongside the standard blocking risk assessment.

How Our FTO Service Covers Swiss Pharmaceutical Products

Our freedom to operate service covers Swiss pharmaceutical FTO across both patent layers — EPO-validated patents and domestic IPI patents — with separate SPC register search, SPC expiry date assessment, and preliminary SPC validity review for blocking SPCs. For generic manufacturers, biosimilar developers, and specialty pharma companies planning Swiss market entry, we structure the FTO to account for all three dimensions of Swiss pharma blocking IP: EPO patents, domestic IPI patents, and SPC extensions with their validity risk profiles. The output gives product teams the complete blocking IP picture — including the challenge opportunities that a two-layer patent search without SPC validity assessment would miss.

Japanese market FTO requires JPO-calibrated claim scope assessment, prosecution history review, and preliminary enablement analysis for broad functional claims. Our service covers all three — giving you a blocking risk picture that reflects Japanese enforcement standards, not US or EPO assumptions. → Contact Us

Conclusion: The Takeaway

Swiss pharmaceutical FTO is a three-dimension analysis: the EPO patent layer, the domestic IPI patent layer, and the SPC extension layer. Missing any one of the three produces an FTO that answers a narrower question than the one the product team actually needs answered. And within the SPC layer, validity assessment is a separate step from identifying active SPCs — because a blocking SPC may be invalid on grounds entirely separate from the underlying patent, and that invalidity is an option the FTO should surface.

The teams that get Swiss pharma FTO right are the ones that cover all three dimensions systematically — not because they are more thorough in general, but because they understand the specific structure of Swiss pharmaceutical IP protection. That structure is the starting point for FTO scope. Getting it right from the beginning is the only way to get the clearance picture that Swiss market entry requires.

The post FTO for Pharmaceutical Products: How SPC Extensions and Domestic Patents Affect Your Clearance appeared first on TT CONSULTANTS.

How Patent Examination Standards Affect What You Need to Clear Before a Product Launch

Vaibhavi Kukreti — Wed, 15 Jul 2026 08:00:05 +0000

Introduction

A product cleared for launch in the US may face a materially different FTO picture when the same analysis is applied to Japan. Not because the product has changed or because the technology is different — but because the JPO examines patents under a different standard from the USPTO and EPO, producing patents with different effective scope, different validity risk profiles, and a different claim construction approach in enforcement proceedings.

Understanding the JPO’s examination standard is not an academic exercise for teams planning Japanese market entry. It is a practical FTO requirement. A FTO analysis that assesses Japanese blocking patents using USPTO or EPO claim scope assumptions will produce wrong answers — sometimes overstating blocking risk, sometimes understating it — because the standards that determine what a Japanese patent actually covers in Japanese proceedings are distinct from both US and European practice.

This article covers the specific ways in which the JPO examination standard differs from USPTO and EPO practice, what those differences mean for FTO blocking risk assessment, and how to structure a Japanese market FTO that reflects the actual Japanese enforcement picture.

How the JPO Examination Standard Differs from USPTO and EPO

Claim scope: narrower at the JPO: JPO-examined patent claims tend to be narrower in scope than equivalent claims examined by the USPTO or EPO. The JPO has historically applied a stricter approach to claim breadth relative to the supporting disclosure, requiring claims to be more closely tied to the specific embodiments described in the specification. For FTO purposes, this means that a Japanese patent covering a technology may have narrower effective blocking scope than a US patent covering what appears to be the same technology — because the claims were examined against a stricter standard and were narrowed during prosecution accordingly.

Enablement: stricter specification requirements: The JPO requires that a specification fully enable a person skilled in the art to practice the invention across the full scope of the claims. Where a claim covers a broad functional class of compounds, methods, or implementations, the specification must demonstrate that the invention works across that class — not just at the specific examples disclosed. This stricter enablement standard means that broad functional claims are more frequently rejected or narrowed during JPO examination than at the USPTO or EPO. For FTO purposes, it also means that broad functional claims in granted Japanese patents may carry higher invalidity risk than they appear to at face value.

Inventive step: closest prior art and technical effect approach: The JPO’s inventive step assessment involves identifying the closest prior art and then assessing whether the claimed difference produces a technical effect that would not have been obvious. This is similar in structure to the EPO’s problem-solution approach, but the JPO applies it in a way that places significant weight on the specification’s disclosure of the technical effect. Claims that assert a technical advantage without adequate specification support face inventive step objections. For FTO, this means that blocking patents with thin technical effect disclosure in the specification may be more challengeable than their grant status suggests.

JPO CONTEXT: The JPO is the world’s third-largest patent office by application volume and has developed a distinct examination culture over decades. JPO examiners work within a tradition of rigorous specification analysis that produces patents with narrower claims and more tightly coupled specification-claim relationships than many other major patent offices. Understanding this culture is the foundation of accurate Japanese FTO analysis.

What JPO Claim Scope Means for FTO Blocking Risk Assessment

One of the most practically important aspects of Japanese FTO is the role of prosecution history in claim construction. As our analysis of FTO for SaaS products in the Japanese market covers in detail, reviewing the prosecution history of potentially blocking Japanese patents is a non-optional FTO step — because the arguments made to the JPO examiner during prosecution significantly influence how Japanese claims are construed in enforcement proceedings.

Literal claim construction as the primary standard: Japanese courts apply literal claim construction as the primary standard for infringement assessment. A product infringes a Japanese patent claim if it performs all the elements of the claim as literally written, taking into account the prosecution history. This more literal approach differs from US claim construction, which applies a range of interpretive tools that often produce broader effective scope than the literal claim language. For FTO, this means that the literal language of each JPO claim element must be mapped precisely to the product feature under analysis — not interpreted through the lens of US claim construction doctrine.

How prosecution history estoppel shapes claim interpretation: Where a Japanese patent applicant made statements during prosecution to narrow a claim — to distinguish prior art or overcome a JPO examiner rejection — those statements create file wrapper estoppel that constrains how courts interpret the granted claim. A claim that appears to cover a product feature on a literal reading of the granted claims may not cover it after prosecution history estoppel is applied. This is why prosecution history review is an essential input to Japanese FTO claim mapping, not an optional supplement.

Doctrine of equivalents: available but applied narrowly: Japan recognizes a doctrine of equivalents, but courts apply it under strict conditions: the substituted element must perform substantially the same function in substantially the same way to achieve substantially the same result; the substitution must have been obvious at the time of infringement; and the element must not have been surrendered during prosecution. The narrow application of equivalents means that design-around options in Japan may be more robust than equivalent alternatives in the US, where a broader doctrine of equivalents applies.

How JPO Enablement Requirements Affect the Validity Dimension of FTO

Broad functional claims carry higher JPO invalidity risk: As noted above, the JPO’s strict enablement requirement means that broad functional claims in granted Japanese patents may be more vulnerable to invalidity challenge than their grant status suggests. For FTO purposes, this creates an important distinction between patents that appear to block and patents that genuinely block. A broad functional claim that was granted at the JPO but has thin specification support for its full claimed scope may be challenged successfully in JPO reexamination or invalidity proceedings.

How enablement assessment changes the FTO risk picture: A complete Japanese FTO includes not just a scope assessment of each blocking patent but also a preliminary validity assessment. For blocking patents with broad functional claims and limited specification support, the FTO should flag the invalidity risk — identifying the patent as a potential challenge candidate alongside the blocking risk assessment. This dual-layer analysis — scope and validity — gives product teams a more accurate picture of genuine blocking risk versus apparent blocking risk in the Japanese patent landscape.

“The Japanese patent that appears to block your product on a literal reading of the granted claims may be narrowed significantly by its prosecution history. And a broad functional claim that survived JPO examination may be more challengeable on enablement grounds than its grant status suggests. Japanese FTO is a two-layer analysis: scope first, validity second.”

How to Calibrate FTO Timing for a Japan Product Launch

FTO timing is always commercially significant, but for Japan it carries particular weight. Our guide on when to conduct an FTO search covers the general timing framework — and for Japan specifically, the recommendation to complete FTO before commercialisation applies with added force because Japanese preliminary injunction proceedings, while less common than in Germany or the UPC, are faster when they occur and can halt market entry before commercial traction is established.

Use J-PlatPat as a primary search database. J-PlatPat is the JPO’s official patent database and contains the most complete and current data on Japanese patent applications and grants. Many international patent databases have incomplete or delayed coverage of Japanese patent data relative to J-PlatPat. A Japanese market FTO that relies only on international database coverage of Japanese patents may miss recent filings and grants that J-PlatPat captures in real time.
Conduct prosecution history review for all high-priority blocking candidates. For every Japanese patent identified as a high-priority blocking candidate in the FTO scope analysis, obtain and review the Japanese-language prosecution history from J-PlatPat. The prosecution history review is the step that translates apparent claim scope into actual enforcement scope under Japanese claim construction standards.
Apply JPO claim construction standards to the blocking risk assessment. For each high-priority blocking patent, conduct the claim mapping under JPO literal claim construction — not US or EPO scope assumptions. Where prosecution history estoppel has narrowed a claim, map the product feature against the narrowed scope. Where the doctrine of equivalents may apply, assess it under Japan’s strict equivalents standard.
Flag broad functional claims for preliminary validity assessment. For blocking patents with broad functional claims and potentially thin specification support, include a preliminary enablement assessment in the FTO output. Patents flagged as potentially weak on enablement grounds are challenge candidates that the product team may prefer to address proactively rather than simply design around.

How Our FTO Service Covers the Japanese Patent System

Our freedom to operate service covers Japanese market FTO with J-PlatPat and JPO native database search, Japanese-language prosecution history review for high-priority blocking candidates, claim scope assessment under JPO literal claim construction standards, doctrine of equivalents analysis under Japan’s strict equivalents criteria, and preliminary enablement validity assessment for broad functional claim blocking patents. For companies planning product launches in Japan for the first time, we structure the FTO to reflect the JPO examination standard that determines actual Japanese patent scope — not a scope assessment calibrated for a different jurisdiction’s examination and enforcement standards.

Conclusion: The Takeaway

The JPO examines patents under a different standard from the USPTO and EPO — narrower claim scope, stricter enablement, more literal claim construction in enforcement proceedings, and a prosecution history that actively shapes how granted claims are interpreted in Japanese courts. A Japanese market FTO that applies US or EPO claim scope assumptions to Japanese blocking patents produces an inaccurate blocking risk picture: sometimes overstating risk where prosecution history has narrowed claims, sometimes understating validity risk where broad functional claims have thin specification support.

The FTO that accurately reflects Japanese market blocking risk is one built on JPO-calibrated claim scope assessment, prosecution history review, and a dual-layer analysis of scope and validity. Getting the Japanese examination standard right is not a refinement to the FTO methodology — it is the foundation of an analysis that actually reflects what Japanese patents cover and what your product needs to clear.

The post How Patent Examination Standards Affect What You Need to Clear Before a Product Launch appeared first on TT CONSULTANTS.

How to Build a Patent Landscape for Emerging Technology: What CNIPA Data Reveals That Global Searches Miss

Vaibhavi Kukreti — Wed, 15 Jul 2026 05:53:02 +0000

Introduction

A patent landscape that covers only English-language databases — USPTO, EPO, Espacenet, Google Patents in English-language filter — captures, at best, a partial picture of the global competitive IP environment in most emerging technology sectors. In many technology areas, it captures a picture that systematically underrepresents one of the world’s largest and most active patent filing jurisdictions.

China is the world’s largest patent filer by volume. In emerging technology areas — AI, 6G, battery technology, quantum computing, electric vehicles — Chinese entities are among the most active global filers. As our analysis of China’s strategic approach to 6G patent filing illustrates, Chinese filing activity in next-generation technology areas is coordinated at a national level, generating patent volumes that shape the global competitive landscape. A landscape that misses this activity is not just incomplete — it is misleading.

This article covers the three structural characteristics of CNIPA data that cause global searches to miss Chinese patent activity, the emerging technology areas where the gap is most consequential, and how to build a landscape that captures the full CNIPA picture.

Why Global Patent Landscape Searches Systematically Miss Chinese Data

Chinese-language filing content: CNIPA patent applications are filed and published in Chinese. English-language database searches — which rely on machine-translated Chinese content or on title-only matching — consistently fail to retrieve a large proportion of relevant Chinese patents. Keyword searches designed for English-language content miss Chinese-language equivalents of the same technical concept.

Domestic-first, PCT-second filing strategy: Many Chinese entities file patent applications at CNIPA first, then file PCT applications in other jurisdictions 12 months later. The PCT application surfaces in international databases. The original CNIPA application may not surface until it is published. In fast-moving technology areas, the CNIPA-first application is the earliest disclosure — and the one that determines the priority date — but it may not appear in a standard global landscape search.

Non-patent literature in Chinese databases: Chinese academic and technical publications in CNKI, Wanfang, and CQVIP represent a body of prior art that is largely invisible to English-language landscape searches. In emerging technology areas where Chinese academic institutions are primary research contributors, this domestic non-patent literature provides critical context for understanding where Chinese innovation is concentrated.

Three Structural Characteristics of CNIPA Data That Require Different Search Methodology

Characteristic 1: Domestic-first filing creates a timing gap. Chinese CNIPA-first applications appear in Chinese databases before their PCT equivalents appear in international databases. Building a landscape that captures the full Chinese filing picture requires searching CNIPA directly — not relying on PCT applications in international databases as a proxy for Chinese patent activity.

Characteristic 2: Chinese-language search terms are necessary. Machine translation of Chinese patent content into English is imperfect and inconsistent. A keyword search designed for English-language content retrieves different results from the same concepts searched in Chinese. Building a complete CNIPA landscape requires Chinese-language keyword searches by analysts with native technical Chinese proficiency.

Characteristic 3: Utility models are a separate data category. Chinese utility model patents are published in a separate CNIPA database category from invention patents. Many global landscape database platforms either do not include Chinese utility models or include them incompletely. A landscape that covers only invention patents misses utility model filings — which in some technology areas represent 30–50% of Chinese patent activity.

Emerging Technology Areas Where the CNIPA Data Gap Is Most Consequential

The CNIPA data gap is most consequential in technology areas where Chinese entities are primary innovation contributors. Our guide on how patent landscape analysis can enhance your R&D strategy covers how landscape outputs translate into R&D investment decisions — and in these technology areas, a landscape that misses the Chinese picture will consistently produce incorrect R&D direction recommendations.

6G and next-generation wireless: China holds over 40% of global 6G-related patent filings. A 6G landscape built on English-language databases alone captures less than 60% of the relevant filings. In a technology area where standardisation and SEP declaration are the primary commercial IP mechanisms, missing 40% of the filing activity fundamentally misrepresents the competitive IP position.

Battery and energy storage technology: Chinese entities including CATL, BYD, and state-affiliated research institutions are among the most active global filers in battery chemistry, cell architecture, and energy management systems. Many of these filings are domestic-first applications that appear in CNIPA before their international counterparts surface in global databases.

AI and machine learning applications: China has the highest volume of AI-related patent applications globally. Tencent, Alibaba, Baidu, Huawei, and dozens of research universities are among the world’s most active AI patent filers. The proportion of their AI filing activity that surfaces in English-language international databases is significantly lower than for US or European filers, because Chinese AI filings are more likely to be domestic-first and Chinese-language-only.

How to Build a Landscape That Captures the CNIPA Picture

Search CNIPA directly in Chinese. Run primary CNIPA searches using Chinese-language keywords developed by native technical Chinese speakers. Use CNIPA’s own classification system rather than relying on USPTO CPC classifications as a search proxy.
Include utility models as a separate search stream. Run a separate utility model search in CNIPA alongside the invention patent search. Utility models cover structural product configurations and represent a distinct patent category that many landscape platforms include incompletely or not at all.
Add Chinese non-patent literature databases. Include CNKI and Wanfang as sources for Chinese academic publications. In technology areas where Chinese academic institutions are primary research contributors, this literature provides both prior art context and an early-stage indicator of where Chinese R&D investment is concentrating before it appears in the patent filing data.
Cross-reference with PCT applications from Chinese entities. Verify that PCT applications from major Chinese filers identified in international searches correspond to CNIPA-first applications already in the Chinese database. Where PCT applications represent a subset of Chinese filing activity, identify the CNIPA-only applications that have not yet been filed internationally.

How Our Landscape Analysis Service Covers CNIPA Data

Our patent landscape analysis service covers CNIPA data with native Chinese-language search methodology, separate utility model search streams, Chinese non-patent literature coverage, and PCT cross-referencing to identify CNIPA-only filings from major Chinese entities. For emerging technology landscapes where Chinese filing activity is commercially significant, we structure the analysis to capture the full CNIPA picture — not just the portion that surfaces in English-language international databases.

Building a patent landscape for an emerging technology where Chinese entities are major filers? Our service covers CNIPA data with native Chinese-language search methodology, utility model coverage, and Chinese non-patent literature. → Contact Us

Conclusion: The Takeaway

A global patent landscape that relies on English-language databases produces a picture of the competitive IP environment that is systematically incomplete in any technology area where Chinese entities are major filers. The gap is structural: Chinese-language filing content, domestic-first timing, utility model patents, and Chinese non-patent literature all require explicit search methodology that most standard landscape approaches do not include.

In emerging technology areas — 6G, battery technology, AI, and others where Chinese national strategy has concentrated R&D investment — the CNIPA data gap is not a minor qualification to the landscape output. It is the difference between a landscape that reflects the competitive IP reality and one that misrepresents it. Building the landscape correctly, with full CNIPA coverage, is the foundation of accurate R&D investment and FTO decisions in these sectors.

The post How to Build a Patent Landscape for Emerging Technology: What CNIPA Data Reveals That Global Searches Miss appeared first on TT CONSULTANTS.

FTO for Market Entry: Why Patent Search Scope Differs Between Domestic and Cross-Border Clearance

Vaibhavi Kukreti — Tue, 14 Jul 2026 10:53:49 +0000

Introduction

Teams that have run thorough FTO searches for US or European market entry and then apply the same methodology to Chinese market entry consistently produce incomplete analyses. Not because the team is less thorough — but because the Chinese patent system has three structural characteristics that require different search scope and different analytical methodology from US and European practice.

Understanding these three differences before scoping a Chinese market FTO is the difference between a clearance that reflects the actual blocking IP picture and one that misses the categories of risk most specific to the Chinese market. Our analysis of the 5 most common pitfalls in FTO analyses identifies scope gaps as the most consequential category of FTO error — and for Chinese market FTO, scope gaps are most consistently caused by these three structural differences.

The three differences are not minor procedural variations. Each one represents a structurally distinct category of blocking IP or analytical methodology that does not have a direct equivalent in US or European FTO practice.

Three Ways Chinese FTO Scope Differs from US and European Practice

Difference 1: Utility Model Patents China grants two types of patents for inventions: invention patents (examined, 20-year term) and utility model patents (unexamined, 10-year term, limited to structural aspects of products). Most international FTO teams search invention patents only. Utility models require a separate search and represent a distinct blocking category that is actively used for enforcement.

Difference 2: Chinese-Language Prosecution History Patent scope in Chinese proceedings is assessed in the context of the prosecution history at CNIPA, which is conducted in Chinese and not captured in English-language patent databases. Statements made during Chinese prosecution create file wrapper estoppel that constrains how courts interpret granted claims.

Difference 3: CNIPA Claim Construction Chinese courts apply a more literal claim construction than US courts and a narrower doctrine of equivalents than EPO proceedings. FTO analysis that applies US or EPO claim scope assumptions to Chinese patents overstates blocking risk; analysis that accounts for Chinese claim construction gives a more accurate picture.

Utility Models: The Blocking IP Category Most FTO Searches Miss

What utility models are: A Chinese utility model patent is granted without substantive examination. Utility models have a 10-year term and are limited to protecting the structural shape, structure, or combination of a product — they cannot protect methods or processes. Despite the lack of substantive examination, utility model patents are fully enforceable rights and can be used to seek injunctions and damages in Chinese courts.

Why they are actively used for enforcement: Because utility model patents are granted without examination, they can be obtained quickly and cheaply relative to invention patents. Chinese companies routinely file utility model patents alongside invention patent applications for the same technology — obtaining faster protection through the utility model while the invention patent is examined. For foreign companies entering the Chinese market, domestic competitors may hold utility model patents covering product configurations that were not identified in an invention-patent-only FTO search.

How to search them: Utility model patents are published in the CNIPA database and searchable separately from invention patents. A complete Chinese market FTO runs two searches: one covering invention patents and one covering utility models in the relevant technology classification. The two searches are not interchangeable — utility models cover structural configurations that may not correspond to the classification structure for method or process invention patents.

Chinese-Language Prior Art and Prosecution History

Why prosecution history matters for FTO: In Chinese patent proceedings, claim scope is assessed in the context of the prosecution history at CNIPA. Where a Chinese patent applicant made statements during prosecution that narrowed the scope of a claim — to distinguish prior art or overcome a CNIPA objection — those statements create file wrapper estoppel that Chinese courts apply when interpreting the granted claim. An FTO analysis that assesses Chinese patent scope from the granted claims alone, without reviewing the Chinese-language prosecution history, may overestimate blocking scope for patents where significant file wrapper estoppel exists.

Non-patent literature in Chinese academic databases: Chinese academic and technical publications — published in Chinese-language databases including CNKI, Wanfang, and CQVIP — represent prior art that may not be captured in international database searches. For technology areas where Chinese academic institutions have been active research contributors, this domestic non-patent literature is a primary prior art source that English-language database searches systematically miss.

CNIPA Claim Construction: How Literal Interpretation Affects FTO

Claim construction methodology is one of the most commonly overlooked FTO variables when teams transition from US or European practice to Chinese market analysis. Our guide on FTO search best practices covers the importance of calibrating claim scope assessment to the jurisdiction-specific construction standard — and for China, that calibration produces materially different FTO conclusions from a US or EPO-based analysis.

More literal than USPTO: Chinese courts and CNIPA apply a more literal interpretation of patent claims than US courts. The US doctrine of claim differentiation, means-plus-function claiming, and the broad range of claim construction tools available in US litigation produce broader effective claim scope than Chinese proceedings typically recognize. An FTO that applies US claim scope assumptions to a Chinese patent overstates the blocking coverage that patent would receive in Chinese enforcement.

Narrower doctrine of equivalents: China has a doctrine of equivalents, but courts apply it narrowly. Equivalents must be obvious to a person skilled in the art at the time of infringement and must essentially perform the same function in the same way to achieve the same result. The narrow application of equivalents means that design-around options that might not avoid infringement under US doctrine may provide genuine clearance in Chinese proceedings.

FTO design-around analysis: These claim construction differences mean that design-around analysis for the Chinese market should be done under Chinese claim construction assumptions, not US or EPO assumptions. An alternative implementation that avoids the literal claim under Chinese construction may provide genuine freedom to operate in China even if the same alternative would not provide clearance under a US claim scope analysis.

“The most consequential FTO error in Chinese market entry is not missing a patent — it is applying the wrong claim construction framework to patents that are found. A patent that appears to block under US doctrine may not block under Chinese claim construction. And a patent that appears narrow under US doctrine may have been applied more literally in Chinese proceedings. The claim construction calibration is where Chinese FTO produces its most distinct results.”

How Our FTO Service Covers Chinese Market Entry

Our freedom to operate service covers Chinese market entry FTO with both invention patent and utility model searches, Chinese-language prosecution history review for blocking candidates, and claim scope assessment under CNIPA claim construction standards. For companies entering the Chinese market for the first time, we structure the FTO to reflect the three structural differences that make Chinese market clearance methodologically distinct from US and European practice — ensuring the search scope and claim analysis reflect the actual blocking IP picture rather than a scope calibrated for a different jurisdiction.

Chinese market entry FTO requires covering utility models, Chinese-language prosecution history, and CNIPA claim construction — three structural differences that standard US or European FTO methodology does not address. Our service covers all three. → Contact Us

Conclusion: The Takeaway

Chinese market FTO is not a US or European FTO with different patent numbers. It is a structurally different analysis that requires a different search scope (utility models alongside invention patents), different analytical inputs (Chinese-language prosecution history), and a different claim construction framework (CNIPA’s more literal approach and narrower doctrine of equivalents).

Teams that apply their domestic FTO methodology to Chinese market entry without accounting for these three differences consistently produce analyses that miss blocking IP, overstate claim scope, and underestimate design-around options. The result is either false clearance or false risk — neither of which serves the product team. Scoping the Chinese market FTO correctly from the start is the only way to avoid both.

The post FTO for Market Entry: Why Patent Search Scope Differs Between Domestic and Cross-Border Clearance appeared first on TT CONSULTANTS.

FTO in the European Market: How to Scope a Search That Covers Both UPC and National Patent Rights

Vaibhavi Kukreti — Tue, 14 Jul 2026 07:54:16 +0000

Introduction

Before June 2023, structuring a European FTO was relatively well-understood. You covered the national designations of European patents in the jurisdictions that mattered commercially — Germany, France, the Netherlands, the UK, Italy — plus any national patents filed directly at domestic patent offices. Each patent was enforced nationally. Each jurisdiction required a separate FTO assessment.

The UPC changed this. European patent protection now comes in two structurally different forms that require different FTO treatment. Patents within the UPC system can be enforced through a single UPC action across all participating states. Patents opted out of the UPC system are enforced nationally, as they always were. A complete European FTO has to account for both — and knowing which form applies to each blocking candidate is now a core component of the FTO scope.

As our review of how the Unified Patent Court is reshaping European IP covers, the UPC has moved faster and more aggressively than many predicted. The enforcement landscape that European FTO needs to account for is meaningfully different from what it was in 2022.

The New European Patent Landscape: Two Parallel Systems

Unitary patents and UPC-system enforcement: The Unitary Patent is a new form of European patent protection that takes effect across all UPC participating states with a single grant. A patent holder who obtains a Unitary Patent holds one right enforceable through the UPC across 17+ member states simultaneously. For FTO purposes, a Unitary Patent in the relevant technology space represents pan-European blocking risk that a single UPC action can enforce.

Traditional European patents within the UPC system: Traditional European patents granted by the EPO that have not been opted out also fall within UPC jurisdiction. Their owners can enforce them through the UPC rather than national courts. For a traditional EP patent that has not been opted out, the enforcement picture is the same as for a Unitary Patent — the patent holder can seek pan-European relief through a single UPC filing.

Opted-out European patents: national enforcement only: European patent owners can register an opt-out that removes their patent from UPC jurisdiction. An opted-out patent can only be enforced through national courts, as under the pre-UPC framework. For FTO purposes, opted-out patents require the same jurisdiction-by-jurisdiction assessment as pre-UPC European patents. Opt-out status is therefore a critical FTO input: it determines which enforcement framework applies to each blocking candidate.

What the UPC System Means for FTO Scope

Opt-out status is the central FTO input: For every European patent identified as a potentially blocking candidate, the first FTO question is whether it is within the UPC system or opted out. This determines whether the blocking risk is pan-European (single UPC action) or national (country-by-country). UPCA opt-out status is registered in the UPC Case Management System and is publicly searchable.

UPC local division geography matters for risk assessment: The most active local divisions — Munich, Düsseldorf, Paris, The Hague, Milan — have different procedural timelines and enforcement tendencies. The relevant local division’s approach to preliminary injunctions affects the FTO risk assessment for each blocking candidate.

UPC preliminary injunction speed amplifies FTO risk: The UPC can issue preliminary injunctions across all participating states within weeks of filing. For a product launching in multiple European markets simultaneously, a UPC-system blocking patent represents a more acute risk than a nationally enforced patent — because enforcement can halt sales across all markets through a single action on a compressed timeline.

PRACTICAL NOTE: As of mid-2026, approximately 40% of traditional European patents in major technology sectors are within the UPC system. The proportion varies by sector: pharma and medtech have higher opt-out rates; electronics and engineering have lower opt-out rates. Sector-specific opt-out pattern data should inform the FTO scope calibration.

What National Patent Rights Mean for FTO Scope

Opted-out European patents: An opted-out traditional EP remains enforceable nationally in each country where it has been validated. The pre-UPC country-by-country enforcement framework applies. Each validated country requires a separate assessment of whether the patent is actively maintained and whether its claims have been amended in national proceedings.

National patents filed directly at domestic offices: Many major European patent holders file national patents directly at domestic patent offices alongside their European patent strategy. In Germany, DPMA-filed national patents are significant in engineering and automotive technology. In France, INPI filings cover pharmaceutical and chemical technology. A European FTO that covers only EP patents misses this layer of national filing activity.

Non-UPC jurisdictions: UK, Switzerland, Norway: The UK, Switzerland, and Norway are not UPC participating states. Patents in these countries are not subject to UPC jurisdiction and require separate national assessment. For products with significant commercial exposure in these markets — particularly the UK and Switzerland in pharma and medtech — national FTO coverage is a separate workstream from the UPC-system analysis.

How to Structure a Complete European FTO

Structuring a complete European FTO in the UPC era requires working through four specific steps. Our guide on when to conduct an FTO search sets out the timing framework — and for European market launches, that timing imperative is amplified by the UPC’s compressed preliminary injunction timeline.

Identify all European patents in the relevant technology space. Run a comprehensive search across EPO-granted patents and Unitary Patents, covering all patent holders including non-obvious holders from adjacent industries with European patent positions in the target technology space.
Check opt-out status for each blocking candidate. For every European patent identified as potentially blocking, check opt-out registration in the UPC Case Management System. Classify each patent as UPC-system (pan-European enforcement risk) or opted-out (national enforcement only). This classification determines the scope of enforcement risk assessment.
Cover national filings in key non-UPC jurisdictions. Run separate national patent searches for UK (UKIPO), Switzerland (IPI), and Norway (Patentstyret) where those markets are commercially significant. Also cover DPMA, INPI, and other major national offices for technology areas where domestic filing alongside European patents is common.
Assess UPC local division preliminary injunction risk. For UPC-system blocking patents where the patent holder is in a jurisdiction with an active local division, assess the preliminary injunction risk timeline and likelihood. This informs the commercial decision about how to manage the blocking risk relative to the product launch timeline.

How Our FTO Service Covers the European Market

Our freedom to operate service covers the full European patent landscape under the UPC-era framework: EP patent searches with opt-out status verification, Unitary Patent coverage, national filing searches in UK, Switzerland, Norway, and key domestic offices, and preliminary injunction risk assessment calibrated to the UPC local division structure. For companies planning European market launches across multiple jurisdictions, we structure FTO engagements to account for both the UPC-system pan-European risk and the national enforcement picture for opted-out and non-UPC-jurisdiction patents.

European FTO now requires covering two parallel patent systems. Our service covers UPC-system patents with opt-out status verification alongside national rights in opted-out jurisdictions and non-UPC markets. → Contact Us

Conclusion: The Takeaway

The UPC has created a genuinely new European patent enforcement landscape — one where a single patent can be enforced pan-European through one action, or enforced nationally through multiple separate proceedings, depending on opt-out status. A European FTO that does not account for this distinction is working with an incomplete picture of the enforcement risk each blocking patent represents.

The complete European FTO now requires four components: comprehensive EP and Unitary Patent identification, opt-out status verification, national filing coverage for non-UPC jurisdictions, and UPC preliminary injunction risk assessment. Missing any one of them produces a FTO that answers a narrower question than the one the product team actually needs answered

The post FTO in the European Market: How to Scope a Search That Covers Both UPC and National Patent Rights appeared first on TT CONSULTANTS.

FTO for Software Products: How to Map Claims When a Patent Covers a Method, Not a Product

Vaibhavi Kukreti — Tue, 14 Jul 2026 05:42:38 +0000

Introduction

The most common FTO approach for hardware products is relatively straightforward: identify the product features, map them against patent claims, assess whether each claimed element reads on a product feature. The question is always about things — components, structures, configurations.

Software patents change this. The majority of software patents are drafted as method claims rather than product claims. A method claim covers how something is done — a sequence of steps performed by a system, a user, or both. When the blocking patent is a method claim, standard feature-to-claim mapping produces the wrong framework. The question is not whether your software ‘has’ the claimed element. It is whether your software ‘performs’ the claimed steps — and who performs them.

This distinction matters because it affects both the scope of the FTO analysis and the infringement analysis that follows. As our piece on the difference between FTO and infringement analysis covers, FTO and infringement analysis ask structurally different questions — and for software method claims, the structural difference is even more pronounced than for hardware products.

Method Claims vs. Product Claims: What the Difference Means for FTO

What a method claim covers: A method claim covers a sequence of steps. Claim 1 of a typical software method patent might read: “A method comprising: receiving user data; processing the data according to algorithm X; generating an output based on the processed data.” The claim does not cover a product that has certain features. It covers the act of performing those steps. Anyone who performs all the steps of the method — in a jurisdiction where the patent is active — potentially infringes, regardless of what their product looks like.

Why method claims dominate software patents: Software patent drafters often prefer method claims because they can be broader than product claims. A product claim for a specific software implementation may be designed around by changing the implementation. A method claim covering the underlying process may not be so easily avoided, because it covers the process regardless of how it is implemented. This makes method claims the more commercially significant claim type for software FTO purposes — and the one that requires the most careful analysis.

Who performs the method matters: For method claim infringement, every step of the method must be performed by a single entity. If your software performs some steps and the user performs other steps, there may not be direct infringement of the method claim — because no single entity performs all the steps. This is the single-entity performance doctrine, and it is one of the most practically significant FTO considerations for software products where user interaction is part of the process the patent covers.

The Three FTO Scenarios Specific to Software Method Claims

Scenario 1: Your software performs all method steps automatically. No user action required to complete the method. The software receives input and performs every claimed step without human intervention. This is the highest-risk scenario: your software directly performs the patented method. Standard FTO mapping applies: map each claimed step to your software’s execution path and assess whether all steps are performed.

Scenario 2: Your platform enables a third party to perform the method. Your software is a platform. Users perform some or all of the claimed method steps using your platform. Direct infringement may not apply (no single entity performs all steps) but induced infringement may: if you specifically instruct users to perform the method and they do, you may be liable for inducing their infringement of the method claim.

Scenario 3: Your software runs on hardware that performs the method. The software is implemented in a device (IoT hardware, medical device, automotive system) and the hardware performs the method steps. The hardware manufacturer, the software developer, and the operator of the device may each have FTO exposure depending on who directs and benefits from each step of the method.

How to Structure FTO Claim Mapping for Method Claims

The methodology for software method claim FTO is covered in detail in our guide on FTO search best practices — and for method claims specifically, the claim mapping process has four steps that differ from standard product claim analysis.

Break the claim into its individual method steps. Method claims are structured as a sequence. List every step separately, including the preamble. Identify which steps are performed by the system, which by the user, and which require interaction between them. This step-by-step breakdown is the foundation of accurate method claim mapping.
Map each step to your software’s execution path. For each claimed step, identify the corresponding function in your software. What code, API call, or user interface action corresponds to each step? Where does your software execute the step? Where does the user execute it? Where is the boundary between system and user action for each step?
Assess the single-entity performance question. After mapping every step, assess whether a single entity — your software system operating without user intervention — performs all the steps. If yes, the direct infringement analysis is straightforward. If no, identify which entity performs which steps and assess whether induced or contributory infringement is in play.
Assess induced and contributory infringement separately. If your software enables users to perform a patented method, assess whether your documentation, user interface design, or marketing communications instruct users to perform the method in the way the patent claims. Induced infringement requires that you knew of the patent and specifically encouraged the infringing acts. Contributory infringement requires that a component of your software has no substantial non-infringing use in the context of the patent. Both are separate analyses from direct infringement.

The Alice/§101 Factor: What Software Patent Eligibility Means for FTO Risk

Alice does not eliminate method claim FTO risk: Since Alice Corp. v. CLS Bank International (2014), many software-implemented method patents have been invalidated under §101 as directed to abstract ideas. This does not mean all software method patents are invalid or that they can be ignored in FTO. A patent that survives Alice scrutiny — or that has not yet been challenged — carries blocking risk regardless of its ultimate validity. FTO identifies blocking patents; validity analysis is a separate assessment.

How to assess validity risk for software method patents: For each software method patent identified as a blocking candidate in the FTO, a validity pre-screen should assess the patent’s Alice exposure. Claims directed to a specific technical implementation rather than a generic abstract idea are more Alice-resilient. Claims that recite a specific technical improvement to computer functionality are the most defensible. A blocking patent with high Alice vulnerability is a candidate for IPR challenge — another tool in the FTO risk management toolkit that is separate from the FTO analysis itself.

How Our FTO Service Covers Software Method Claims

Our freedom to operate service covers software method claim analysis with step-by-step execution path mapping, single-entity performance assessment, and induced and contributory infringement evaluation. For software products where method claim exposure is a primary FTO risk, we structure the analysis around the three scenarios above — direct execution, platform-enabled user performance, and hardware-embedded method performance — giving product teams a clear picture of which method claims present genuine risk and what the most viable risk mitigation paths are.

Software FTO requires a different methodology when the blocking patent is a method claim. Our service covers step-level execution mapping, single-entity performance analysis, and induced infringement assessment — the three analyses that standard product claim FTO misses. → Contact Us

Conclusion: The Takeaway

Method claims are the dominant claim type in software patents. They cover processes, not products — which means the standard hardware FTO framework of feature-to-claim mapping does not produce accurate results when applied directly to software method claims. The correct framework breaks the method into individual steps, maps each step to the software’s execution path, assesses single-entity performance, and evaluates induced and contributory infringement separately.

The companies that get this right are the ones whose software FTO analysis actually reflects the method claim risk their products face. The ones that apply hardware FTO logic to software method claims are the ones that discover the gap — at the worst possible time — when a blocking method patent is asserted after launch. Method claim FTO is a methodological question, not just a search scope question. Getting the methodology right is the difference between a search that clears the product and one that misses the risk.

The post FTO for Software Products: How to Map Claims When a Patent Covers a Method, Not a Product appeared first on TT CONSULTANTS.